Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT study
Authors' conclusion
Including pioglitazone plus exenatide in the glucose-lowering regimen slows the progression of cIMT and was associated with lower hepatic fat content and fibrosis compared with subjects receiving sequential add-on therapy without pioglitazone and exenatide despite comparable optimal glycemic control.
Study context
- Population
- Patients with new-onset T2D who maintained HbA1c<6.5% for 6 years in EDICT
- Participants
- 29 vs 26
- Comparison
- Initial triple therapy vs sequential add-on therapy
- Initial triple therapyn = 29
- Sequential add-on therapyn = 26reference
- Primary endpoint
- cIMT and liver fat content
- Follow-up
- 6 years
Primary result
As reported in the abstract
- Sequential add-on therapy had a greater increase in carotid intima-media thickness (cIMT) than initial triple therapy
- Sequential add-on therapy had greater liver fat content and fibrosis than initial triple therapy
Further findings
HbA1c · 6 years
P = NS
Original publication
Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT study. BMJ Open Diabetes Res Care. Published 27 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →